title: The tumour necrosis factor receptor superfamily member 1b 676T>G polymorphism in relation to response to infliximab and adalimumab treatment and disease severity in rheumatoid arthritis.
abstract: OBJECTIVE
  To assess the effect of a functional polymorphism (676T>G, M196R) in the tumour necrosis factor receptor super family 1b (TNFSF1b) gene on disease activity, radiological joint damage and response to infliximab and adalimumab treatment in patients with rheumatoid arthritis (RA).
  
  
  METHODS
  Two cohorts of patients with RA were genotyped for the 676T>G polymorphism (rs1061622) in exon 6 of the TNFSF1b gene by restriction fragment length polymorphism analysis. One cohort (n = 234) included patients from the Dutch Rheumatoid Arthritis Monitoring register with detailed information on their response to anti-TNF therapy (infliximab and adalimumab), the other cohort comprised patients from a long-term observational early inception cohort at our centre (n = 248).
  
  
  RESULTS
  The 676T>G polymorphism was not associated with anti-TNF response after 3 or 6 months of treatment. Linear regression analysis showed no significant difference in the progression of radiological joint damage during the first 3 and 6 years of disease between the three genotype groups (TT, TG and GG). Additionally, no difference in mean disease activity between genotypes was seen after 3 and 6 years of disease.
  
  
  CONCLUSIONS
  Despite its demonstrated functionality, the 676T>G polymorphism in the TNFSF1b gene does not have a major role in either the response to anti-TNF therapy or in the disease severity or radiological progression in RA.
authors.affiliation: Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
authors.forename: E J M
authors.initials: EJ
authors.lastname: Toonen
authors.forename: M J H
authors.initials: MJ
authors.lastname: Coenen
authors.forename: W
authors.initials: W
authors.lastname: Kievit
authors.forename: J
authors.initials: J
authors.lastname: Fransen
authors.forename: A M
authors.initials: AM
authors.lastname: Eijsbouts
authors.forename: H
authors.initials: H
authors.lastname: Scheffer
authors.forename: T R D J
authors.initials: TR
authors.lastname: Radstake
authors.forename: M C W
authors.initials: MC
authors.lastname: Creemers
authors.forename: D-J R A M
authors.initials: DJ
authors.lastname: de Rooij
authors.forename: P L C M
authors.initials: PL
authors.lastname: van Riel
authors.forename: B
authors.initials: B
authors.lastname: Franke
authors.forename: P
authors.initials: P
authors.lastname: Barrera
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000235:genetics* / Q000276:immunology; D001175:Arthrography; D016022:Case-Control Studies; D005260:Female; D005838:Genotype; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D000069285:Infliximab; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D012150:Polymorphism, Restriction Fragment Length; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000235:genetics; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D047888:Receptors, Tumor Necrosis Factor, Type I; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab